Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 281,735
  • Shares Outstanding, K 48,743
  • Annual Sales, $ 15,840 K
  • Annual Income, $ -308,480 K
  • EBIT $ -200 M
  • EBITDA $ -188 M
  • 60-Month Beta 0.90
  • Price/Sales 17.98
  • Price/Cash Flow N/A
  • Price/Book 5.10

Options Overview Details

View History
  • Implied Volatility 126.48% ( -0.57%)
  • Historical Volatility 94.09%
  • IV Percentile 89%
  • IV Rank 67.99%
  • IV High 180.71% on 07/03/24
  • IV Low 11.27% on 05/07/24
  • Put/Call Vol Ratio 0.08
  • Today's Volume 609
  • Volume Avg (30-Day) 1,465
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 41,360
  • Open Int (30-Day) 37,232

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.43
  • Number of Estimates 5
  • High Estimate 1.24
  • Low Estimate -1.00
  • Prior Year -1.53
  • Growth Rate Est. (year over year) +71.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.35 +8.04%
on 11/05/24
7.96 -27.39%
on 11/11/24
-0.87 (-13.08%)
since 10/22/24
3-Month
4.45 +29.89%
on 10/03/24
7.96 -27.39%
on 11/11/24
-0.72 (-11.15%)
since 08/22/24
52-Week
3.73 +54.96%
on 07/05/24
11.35 -49.07%
on 07/10/24
-1.01 (-14.87%)
since 11/22/23

Most Recent Stories

More News
uniQure N.V. Initiates Phase I/IIa Clinical Trial for AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

uniQure initiates GenTLE trial, dosing first patient with AMT-260 for refractory mesial temporal lobe epilepsy treatment.Quiver AI SummaryuniQure N.V. announced the dosing of the first patient in its GenTLE...

QURE : 5.78 (-1.11%)
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

QURE : 5.78 (-1.11%)
UniQure: Q3 Earnings Snapshot

UniQure: Q3 Earnings Snapshot

QURE : 5.78 (-1.11%)
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

QURE : 5.78 (-1.11%)
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

QURE : 5.78 (-1.11%)
UniQure: Q2 Earnings Snapshot

UniQure: Q2 Earnings Snapshot

QURE : 5.78 (-1.11%)
UniQure: Q1 Earnings Snapshot

UniQure: Q1 Earnings Snapshot

QURE : 5.78 (-1.11%)
UniQure: Q3 Earnings Snapshot

UniQure: Q3 Earnings Snapshot

QURE : 5.78 (-1.11%)
Why Shares of uniQure Are Up Thursday

The company announced a reorganization that included layoffs.

QURE : 5.78 (-1.11%)
Why Shares of uniQure Are Dropping Tuesday

The company is facing being delisted from the S&P 600 Index.

QURE : 5.78 (-1.11%)

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

3rd Resistance Point 6.21
2nd Resistance Point 6.10
1st Resistance Point 5.94
Last Price 5.78
1st Support Level 5.66
2nd Support Level 5.55
3rd Support Level 5.39

See More

52-Week High 11.35
Fibonacci 61.8% 8.44
Fibonacci 50% 7.54
Fibonacci 38.2% 6.64
Last Price 5.78
52-Week Low 3.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar